Novartis has signed a collaboration agreement and option to acquire Cellerys, a Zurich-based startup conducting research on a therapy to fight multiple sclerosis (MS), the Swiss drugmaker announced on Tuesday, June 1.
“Under the agreement, Novartis will support the development of the CLS12311 therapy currently in Phase 2” study, the Basel-based drugmaker said in a statement. “Novartis will have the option to acquire Cellerys upon completion of a Phase 2 trial in the coming years.”
Cellerys was founded in 2015 as a University of Zurich spin-out by MS researchers. No financial details for the transaction were given by Novartis.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
